NEUROCRITICAL CARE, cilt.7, sa.3, ss.194-202, 2007 (SCI-Expanded)
Objective To evaluate the safety of high-dosages of the endothelin ETA/B receptor antagonist bosentan in SAH patients at high-vasospasm risk.